
Triple receptor agonist (GLP-1, GIP and glucagon receptor), research code LY3437943. A metabolic research peptide, studied in relation to glucose homeostasis and metabolic regulation in preclinical research.
Research areas
Extra options

1 ml insulin needles
10 stuks · €5,00/pak

0.5 ml insulin needles
10 stuks · €5,00/pak
Triple receptor agonist (GLP-1, GIP and glucagon receptor), research code LY3437943. A metabolic research peptide, studied in relation to glucose homeostasis and metabolic regulation in preclinical research.
Retatrutide (development code LY3437943) is a synthetic peptide under clinical investigation. It differs from earlier generations of incretin analogues in targeting three receptors at once rather than one or two. That threefold action is why the literature refers to it as a triple agonist.
The three receptors are GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and the glucagon receptor. For comparison, semaglutide targets one receptor and tirzepatide two. Each receptor has its own role in glucose and energy regulation, and the published literature is largely concerned with how the three signalling routes interact.
Retatrutide holds no marketing authorisation anywhere. It is in clinical development and the published research spans phase 1 through phase 2. That distinction is not administrative: semaglutide and tirzepatide are authorised medicines in the European Union; retatrutide is not. We supply it solely as laboratory material for in-vitro research.
The peptide is supplied as a lyophilised (freeze-dried) powder. In that form it is stable for extended periods at low temperature, which is what makes it suitable for transport and storage before reconstitution in a laboratory.
The areas below recur in the published literature on this molecule. They are directions of research, not applications — no statement is made about efficacy or suitability for any use.
Retatrutide is only as useful as research material as the documentation that comes with it. This is what we record per batch:
Lyophilised and unopened, the peptide is kept cool, dry and dark. Brief exposure to room temperature in transit is normal for the powder, and is precisely why it ships in this form.
The literature generally uses bacteriostatic water for reconstitution. Once reconstituted the solution has a limited shelf life and belongs in refrigerated storage. Exact conditions vary by protocol; we prescribe none.
The publications below are the primary literature on this molecule. They are listed as a pointer to published research and are not a claim about this product.

Retatrutide
5 mg · €49,95